Treatment with a platelet-activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock.

Date publication

mars 2020

Journal

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GENY Bernard

Tous les auteurs :
Tacquard C, Oulehri W, Collange O, Garvey LH, Nicoll S, Tuzin N, Geny B, Mertes PM

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31755606

Résumé

In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet-activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.

Mots clés

anaphylaxis, epinephrine, ovalbumin, platelet-activating factor, shock

Référence

Clin Exp Allergy. 2020 03;50(3):383-390